RDHL (MC $61 M) FDA deicison on Feb 3 // 2 more NDA filings in 2014 // Float 4 M
RDHL is another brutally Underpriced and Unknown Biotech Stock . Here are the reasons why this low float Gem is a MUST HAVE for every Biotech investor :
1) Very Promising Pipeline with multiple potential Blockbusters 2) FDA decision for first Drug (migraine) on February 3 3) Another 2x NDA Filings soon one in 1Q and one in 2H 2014 4) Another 2 Drugs in Phase 3 5) Very low Burn-rate of only $10 M per year 6) Enough Cash untill mid 2015 Excluding cash from new Partnerships 7) Dirt Cheap with a Market cap of just $61 M 8) Ultra low float with only 4.2 M shares 9) Top Management ( they have one of the most successful director in the pharma area on their board , see below the info to this guy )
I think this low float stock has everything to hit minimum $50++ within 2014 .For me RDHL is currently my top favorite stock in the Biotech sector . GL
Redhill (RDHL)
Market Cap: $61 M Cash: $14.7 M Price: $9.80
Shares Out: 6.3 M (Management alone holding over 2.6 M shrs) Float: 4.2 M
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind is a member of Teva’s board of directors.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.